Amarin Co. plc (NASDAQ:AMRN – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for shares of Amarin in a report released on Tuesday, July 11th. Cantor Fitzgerald analyst L. Chen anticipates that the biopharmaceutical company will earn ($0.18) per share for the year. The consensus estimate for Amarin’s current full-year earnings is ($0.15) per share. Cantor Fitzgerald also issued estimates for Amarin’s FY2024 earnings at $0.07 EPS.
Separately, StockNews.com began coverage on shares of Amarin in a research note on Thursday, May 18th. They issued a “hold” rating for the company.
Amarin Price Performance
Amarin (NASDAQ:AMRN – Get Free Report) last released its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Amarin had a negative net margin of 25.16% and a negative return on equity of 15.45%. The company had revenue of $85.98 million during the quarter, compared to the consensus estimate of $82.58 million.
Hedge Funds Weigh In On Amarin
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMRN. HighTower Advisors LLC boosted its holdings in shares of Amarin by 30.2% in the first quarter. HighTower Advisors LLC now owns 73,466 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 17,042 shares during the period. Clearbridge Investments LLC increased its stake in shares of Amarin by 0.9% in the 1st quarter. Clearbridge Investments LLC now owns 4,789,575 shares of the biopharmaceutical company’s stock valued at $15,758,000 after acquiring an additional 42,012 shares during the last quarter. UBS Group AG boosted its position in Amarin by 0.9% during the 1st quarter. UBS Group AG now owns 880,081 shares of the biopharmaceutical company’s stock worth $2,895,000 after acquiring an additional 7,994 shares during the last quarter. State Street Corp raised its stake in Amarin by 7.7% in the 1st quarter. State Street Corp now owns 172,596 shares of the biopharmaceutical company’s stock valued at $568,000 after acquiring an additional 12,298 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Amarin by 82.4% in the first quarter. Goldman Sachs Group Inc. now owns 774,484 shares of the biopharmaceutical company’s stock worth $2,549,000 after purchasing an additional 349,764 shares during the period. Institutional investors and hedge funds own 24.50% of the company’s stock.
Amarin Company Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Further Reading
- Five stocks we like better than Amarin
- Delta Takes Flight: Double-Digit Upside In Sight
- Generac Powers Up as Summer Temperatures Rise
- 3 Reasons Why Rivian Can Continue To Surge Higher
- Despite Breaking Higher, Analysts Remain Cautious HP Inc.
- PepsiCo Can Soar To New Highs In The 2nd Half
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
